普洛药业(000739) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,730,189,121.97, a decrease of 14.63% compared to ¥3,198,046,619.86 in the same period last year[5] - Net profit attributable to shareholders was ¥248,547,145.11, representing a slight increase of 1.98% from ¥243,716,289.99 year-on-year[5] - The basic and diluted earnings per share were both ¥0.2126, reflecting a growth of 2.02% from ¥0.2084 in the same period last year[5] - Net profit increased to ¥248,576,261.58 compared to ¥243,714,001.08, showing a growth of approximately 2.3%[18] - The total profit margin for the period was approximately 10.9%, slightly down from the previous margin of 11.1%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥14,993,469.16, a decline of 105.35% compared to ¥280,125,473.87 in the previous year[5] - Operating cash flow generated a net outflow of ¥14,993,469.16, contrasting with a net inflow of ¥280,125,473.87 in the previous period[19] - Cash and cash equivalents decreased to CNY 3,465,233,609.71 from CNY 3,661,618,802.74, reflecting a decline of approximately 5.36%[14] - Cash and cash equivalents at the end of the period stood at ¥2,594,930,339.41, slightly down from ¥2,599,072,264.47[20] - Investment activities resulted in a net cash outflow of ¥91,370,688.15, compared to a larger outflow of ¥188,142,141.05 in the prior period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,708,540,956.72, a slight decrease of 0.16% from ¥12,729,008,610.16 at the end of the previous year[5] - Current assets totaled CNY 8,228,646,015.77, compared to CNY 8,186,761,774.66 at the start of the period, indicating a growth in liquidity[14] - Total liabilities decreased to CNY 5,709,989,761.76 from CNY 5,979,125,430.44, indicating a reduction of about 4.49%[15] - The company's equity attributable to shareholders increased to CNY 6,990,603,683.93 from CNY 6,741,964,785.16, reflecting an increase of approximately 3.69%[16] - Short-term borrowings decreased to CNY 668,156,422.52 from CNY 814,026,241.34, a reduction of about 17.94%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,719, with the largest shareholder holding 28.30% of the shares[10] - The company repurchased 10,880,000 shares, representing 0.93% of the total share capital[11] Investment and Other Income - The company reported a significant increase in investment income to ¥39,456,689.06, compared to a loss of -¥2,018,356.21 in the previous year[9] - Non-recurring gains and losses totaled ¥42,881,422.13, primarily from the disposal of non-current assets and government subsidies[6] Research and Development - Research and development expenses increased to ¥169,688,023.08 from ¥152,938,500.76, reflecting a rise of about 11%[17] Other Financial Metrics - The company's return on equity (ROE) was 4.00%, an increase of 0.16% compared to 3.84% from the previous year[5] - Accounts receivable financing increased by 195.96% to ¥539,323,041.79, mainly due to an increase in received bills[9] - Accounts receivable increased to CNY 1,832,342,320.15 from CNY 1,764,198,282.30, representing a growth of about 3.86%[14] - Inventory decreased to CNY 1,651,614,838.63 from CNY 1,860,088,103.67, showing a decline of approximately 11.21%[14] - The company reported a significant increase in long-term receivables, rising to CNY 3,888,628.75 from CNY 3,483,230.30, an increase of approximately 11.63%[15] - The company experienced a foreign exchange impact of ¥3,246,242.93 on cash and cash equivalents[20]